Clinical Trials Browser

Phase 2 × Breast Neoplasms × Alpelisib × Clear all

Breast Neoplasms

NCT03056755 2026-01-13

BYLieve

Phase 2 Completed

383 enrolled 16 charts

Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

24 enrolled

Breast

Breast Neoplasms

NCT04216472 2025-09-30

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Phase 2 Terminated

6 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05392608 2025-09-17

SEQUEL-Breast

Phase 2 Active not recruiting

130 enrolled

Breast

Breast Neoplasms, Genetic Diseases, Inborn

NCT05625087 2025-08-20

SAFIR 03

Phase 2 Active not recruiting

162 enrolled

Breast

Breast Neoplasms

NCT04300790 2025-07-29

METALLICA

Phase 2 Completed

69 enrolled

BreastEndocrine

Breast Neoplasms, Hyperglycemia, Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

NCT04899349 2024-10-09

EPIK-B4

Phase 2 Terminated

2 enrolled 8 charts

Breast

Breast Neoplasms, Hyperglycemia, Hereditary Sensory and Autonomic Neuropathies

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

400 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT03386162 2022-11-28

SAFIR-PI3K

Phase 2 Terminated

31 enrolled

Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT02506556 2022-08-16

PIKNIC

Phase 2 Completed

38 enrolled

Breast

Breast Neoplasms

NCT01923168 2018-09-14

Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women

Phase 2 Completed

340 enrolled 39 charts

Breast

Breast Neoplasms

Clinical Trials

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

BYLieve

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

SEQUEL-Breast

SAFIR 03

METALLICA

EPIK-B4

ROME

SAFIR-PI3K

PIKNIC

Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women